



HAL
open science

Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)

Camille Villon, Laure Orgeolet, Anne-Marie Roguedas, Laurent Misery, Jacques-Eric Gottenberg, Divi Cornec, Sandrine Jousse-Joulin, Raphaele Seror, Jean-Marie Berthelot, Philippe Dieude, et al.

► To cite this version:

Camille Villon, Laure Orgeolet, Anne-Marie Roguedas, Laurent Misery, Jacques-Eric Gottenberg, et al.. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). *Joint Bone Spine*, 2021, 88 (4), pp.105162. 10.1016/j.jbspin.2021.105162 . hal-03169298

HAL Id: hal-03169298

<https://hal.science/hal-03169298>

Submitted on 15 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)

Camille Villon (1) ; Laure Orgeolet (1) ; Anne-Marie Roguedas (1) ; Laurent Misery (1) ;
Jacques-Eric Gottenberg (2) ; Divi Cornec (3) ; Sandrine Jousse-Joulin (3) ;
Raphaelle Seror (4) ; Jean-Marie Berthelot (5) ; Philippe Dieude (6) ; Jean-
Jacques Dubost (7) ; Anne-Laure Fauchais (8) ; Vincent Goeb (9) ; Eric Hachulla (10) ;
Pierre-Yves Hatron (10) ; Claire Larroche (11) ; Gilles Hayem (12) ; Véronique Le
Guern (13) ; Aleth Perdriger (14) ; Jacques Morel (15) ; Olivier Vittecoq (16) ;
Xavier Mariette (4) ; Valérie Devauchelle-Pensec (3) ; and Alain Saraux (3)

(1) Dermatologie, CHU de Brest, 29200 Brest

(2) Rhumatologie, CHU de Strasbourg, Hôpitaux Universitaires Strasbourg, 67000
Strasbourg

(3) Rhumatologie, CHU de Brest, Université de Bretagne Occidentale, INSERM 1227,
LabEx IGO, centre de référence maladies rares CERAINO, 29200 Brest

(4) Rhumatologie, Université Paris Sud XI, APHP, 94270 Le Kremlin-Bicêtre

(5) Rhumatologie, CHU Hôtel Dieu, 44093 Nantes

(6) Rhumatologie, Hôpital Bichat-Claude Bernard, 75018 Paris

(7) Rhumatologie, CHU Gabriel-Montpied, 63003 Clermont-Ferrand

(8) Médecine interne, CHU de Limoges Dupuytren, 87042 Limoges

(9) Rhumatologie, CHU Amiens-Picardie Site Nord, 80054 Amiens

(10) Service de Médecine interne et Immunologie Clinique, Université de Lille, CHU,
centre de référence des maladies rares autoimmunes rares (CeRAINO), 59100 Lille

(11) Médecine interne H5, C.H.U. Hôpital Avicenne, 93000 Bobigny

(12) Service de Rhumatologie, CHU Ambroise Paré, 92100 Boulogne-Billancourt,

(13) Médecine Interne, Hôpital Cochin, 75679 Paris

(14) Rhumatologie, Hôpital Sud, 35200 Rennes

(15) Immuno-Rhumatologie, CHU Lapeyronie, 34000 Montpellier

(16) Rhumatologie, CHU Rouen, 76000 Bois-Guillaume

all in France.

Corresponding author: Prof. Alain Saraux, Rheumatology Unit, Hôpital de la Cavale
Blanche, BP 824, F 29609 Brest Cedex, France
Phone: +33 298 347 268; Fax: +33 298 493 627
E-mail: alain.saraux@chu-brest.fr

ABSTRACT

Objective

To determine the prevalence and significance of dermatological disorders in primary Sjögren syndrome (pSS).

Methods

We used 2 pSS French cohorts (ASSESS, in which prevalence of skin disorders in 395 patients was evaluated; and diapSS, in which 76 on 139 pSS patients had an examination by a dermatologist) and baseline data of the TEARS randomized trial (110 patients with recent or active pSS treated with rituximab or placebo and evaluated for skin dryness using a visual analogue scale (VAS) out of 100).

Results

Skin manifestations included in the EULAR Sjögren syndrome disease activity index (ESSDAI) were rare in the ASSESS cohort (n=16/395, 4.1%, mainly purpuras; only 3 had high activity), but they were associated with activity in the other ESSDAI domains (peripheral neurological (p<0.001), muscular (p<0.01), haematological (p<0.05), biological (p<0.05), history of arthritis (p<0.01), splenomegaly (p<0.05) and higher gamma globulin levels (p<0.01)). In the diapSS cohort, compared to pSS patients not receiving a dermatological consultation, the pSS patients who had a dermatological consultation had significantly more dermatological involvement outside the ESSDAI score [38.2% (29/76) versus 15.9% (10/63); p<0.01]. The TEARS study showed a high prevalence of cutaneous dryness (VAS>50; 48.2%) and found that patients with dry skin had higher VAS pain (p<0.01) and drought (p<0.01) scores.

Conclusion

ESSDAI skin activity is rare and associated with hypergammaglobulinemia and ESSDAI activity. Systematic dermatological examination is informative for non-specific lesions. The most common skin disorder is skin dryness, which is associated with a higher pain and overall subjective dryness.

Key words:

skin; cutaneous involvement; dryness; sicca; Sjogren syndrome; disease activity; visual analogic score; rheumatology; cohort; rituximab

1. Introduction

Sjögren syndrome is a systemic autoimmune disease characterized by lymphoid infiltration of the salivary glands and lacrimal glands resulting in secretory dysfunction, and is clinically manifested as xerostomia, xerophthalmia, dry skin, vaginal, respiratory (1–3) and extraglandular involvement of skin, joints, lungs, nervous system and kidneys (1,4–6). Sjögren syndrome may be primary or associated with another systemic autoimmune disease (lupus, inflammatory myopathy or scleroderma) or organ-specific autoimmune disease (such as autoimmune thyroiditis or primary biliary cirrhosis). At present, pSS is classified using the 2002 Americano-European Criteria Group (AECG) criteria (7) or 2016 American College of Rheumatology /European Ligue Against Rheumatism (ACR–EULAR) criteria (8,9).

The EULAR task force on pSS has created two new tools for assessing disease activity and patient-reported outcomes. The EULAR Sjögren syndrome disease activity index (ESSDAI) (1) is the sum of scores for each organ-specific domain multiplied by the activity level (range 0–3). The EULAR Sjögren syndrome patient reported index (ESSPRI) (10) combines visual analogue scales (VASs) for dryness, pain and fatigue.

Cutaneous involvement is common during primary Sjögren syndrome (pSS), but prevalence and characteristics are difficult to establish precisely because of the limited number of patients studied in most cohorts, the variability of the disorders evaluated in each cohort, the rarity of some of these disorders, and the heterogeneity of evaluations from previous studies (11).

The main objective of this study was to determine, using 3 French groups of patients suffering from pSS (ASSESS, diapSS, TEARS) in which different evaluation criteria were used, the prevalence of dermatological disorders and the clinical and paraclinical parameters associated with them. We sought to assess, on the one hand, the prevalence of cutaneous lesions according to the ESSDAI score at inclusion (cutaneous manifestations contributing to the ESSDAI value are erythema multiforme and cutaneous vasculitis, the most frequent being vascular purpura, and urticarial vasculitis (1)); and on the other hand, the other dermatological features since the cutaneous domain of ESSDAI is limited to few signs and does not include skin and mucosal dryness.

2. Methods

We used data from two French cohorts (*ASSESS*, which evaluated the prevalence of skin disorders in 395 pSS patients, and *diapSS* including 139 patients who had Sjögren syndrome diagnosed according to 2016 ACR-EULAR criteria among 325 patients suspected of having primary Sjögren syndrome and baseline data from the *TEARS* randomized trial (110 patients with recent or active pSS treated with rituximab or placebo evaluated for skin dryness using a visual analogue scale out of 100).

2.1. Patients

2.1.1. Evaluating Systemic Signs and Evolution of Sjögren Syndrome (*ASSESS*)

ASSESS was a prospective multicentre national cohort study. Its primary objective was to identify factors predicting systemic complications and lymphoma in pSS during a prospective 5-year follow-up. This cohort was created in 2006 (Hospital Clinical Research Program 2005, P060228). A total of 395 consecutive patients who met the American-European Consensus Group (AECG) criteria were included in 15 centres of tertiary autoimmune diseases between 2006 and 2009. The study, promoted by the Assistance Publique des Hôpitaux de Paris, was approved by the Ethics Committee of Bichat Hospital and the National Commission for Computing and Liberties in 2006. All patients gave their written consent with full knowledge of the facts.

2.1.2. *DiapSS*

DiapSS was a single-centre Brittany cohort study of patients suspected of having a diagnosis of pSS who were prospectively included between January 2006 and September 2016 at the University Hospital Brest, France. The criteria for inclusion in the cohort were subjective ocular or mouth dryness, major salivary gland swelling, extraglandular manifestations suggestive of pSS, or suggestive antibodies or biological abnormalities. The patients were referred to our multidisciplinary clinics by their family doctor, rheumatologist, internist, oral specialist or ophthalmologist. A total of 325 patients were included prospectively, 139 of whom fulfilled the ACR/EULAR criteria of pSS (8). All participants signed an informed consent form, and the study was approved by the local ethics committee (Brest University Hospital).

2.1.3. *TEARS*

TEARS was a French national multicentre cohort study whose objective was to evaluate the efficacy of rituximab in terms of improvement in absolute value of + 30% on at least two of the following four visual analogue scales: drought, pain, fatigue, and global evaluation. A total of 110 patients with pSS meeting the criteria of AECG and having active disease (defined by score > 50 mm on at least two of the four visual analogic scores (VASs): overall assessment of the disease, pain, dryness, fatigue) were included prospectively between 2008 and 2011 by French internists and rheumatologists in 14 French university hospitals. All patients had to have recent (less than 10 years after the first manifestation reported to or observed by a physician) or active Sjögren syndrome with active visceral involvement. This study was approved by the relevant ethics committee (PPC West VI), and all patients gave their written consent prior to study enrolment. The protocol was registered on ClinicalTrials.gov (NCT00740948).

2.2. Methods

For the three cohorts, all systemic manifestations [skin, joints, lungs, kidneys, peripheral nervous system (PNS), central nervous system (CNS), muscles and vessels] were prospectively documented through a standardized paper report (CRF) by a pSS expert clinician at inclusion. The systemic activity of the disease was evaluated by the ESSDAI score (range: 0 to 123), including 12 domains (1). The ESSPRI score (patient-related index linked to the EULAR Sjögren syndrome score), a consensus result obtained by the patient assessing dryness, fatigue and pain, was completed by all patients each year (10). In the *TEARS* cohort, we also included a VAS score for cutaneous dryness collected at baseline. In the *DiapSS* cohort, a dermatologist examined patients with suspicion of pSS when possible.

2.3. Statistical analysis

We analysed the baseline patient characteristics for which the relevant data were available. In the *diapSS* cohort, we compared patients having a dermatological examination with those who did not. In the *ASSESS* cohort, we compared patients with skin manifestations, either past and/or present, to patients with no cutaneous manifestations. In the *TEARS* cohort, we compared patients with a VAS cutaneous dryness score ≥ 50 to those with VAS cutaneous dryness < 50 .

Continuous variables were described as the mean \pm SD and were compared using the Mann-Whitney test. Categorical variables were described as n (%) with the 95% confidence interval and compared using the Pearson's chi-square test. SPSS software version 25.0 [IBM, Armonk, NY, USA] was used for all analyses. All significance tests were two-tailed, and values of $p < 0.05$ were considered significant.

3. Results

3.1. Studied population

We evaluated data from 644 pSS and 186 sicca patients without pSS. Table 1 lists the main characteristics of the patients in the three cohorts. The patients were mainly women. The mean age at diagnosis was between 54.3 and 57.9 years in the three cohorts. The mean ESSDAI score was higher in the TEARS study than in the two cohorts, and the prevalence of cutaneous manifestation according to the ESSDAI score was also slightly higher.

3.2. Cutaneous involvement

In the ASSESS cohort, cutaneous manifestations contributed to the ESSDAI value in 16/395 (4.1%) patients, including 3 with high, 12 with moderate, and 1 with low disease activity. Forty-four patients had a history of purpura, including 9 with purpura present at baseline; 16 patients had a history of livedo, including 4 with livedo present at baseline; and 4 patients with a history of ulcer, including 1 patient with ulcer present at baseline. In total, cutaneous manifestations contributing to the ESSDAI at baseline and/or previously have been reported at any visit value in 64/391 patients (16.4%) (Table 2). Data about cutaneous manifestations outside the ESSDAI were not collected and we cannot describe them.

In the diapSS cohort of 319 patients, 91 had cutaneous involvement (in score ESSDAI and out of score ESSDAI; 46 pSS and 45 patients suspected of pSS but not fulfilling the ACR/EULAR criteria of pSS). Cutaneous manifestations contributed to the ESSDAI value in 7/139 (5.0%) pSS patients. In pSS patients, 39 had a cutaneous involvement not taken account in the ESSDAI score (28.1%) (Table 3). Thirty two of 139 pSS patients (27.3%) had Raynaud's syndrome. In the diapSS cohort, 139 pSS patients fulfilled the ACR/EULAR

criteria of pSS and 76 of them received a dermatological consultation. Compared to pSS patients not receiving a dermatological consultation, the pSS patients who had a dermatological consultation did not present more cutaneous involvement included in the ESSDAI score but they had significantly more dermatological involvement outside ESSDAI score ($p < 0.01$) (Table 4).

In the TEARS cohort, cutaneous manifestations contributed to the ESSDAI value in 7/110 (6.4%) patients, including 3 with high, 3 with moderate, and 1 with low disease activity. The mean VAS score for cutaneous dryness was 45.1 (SD, 31.5). Fifty-three of 110 patients (48.2%) had a VAS skin dryness score ≥ 50 .

3.3. Factors associated with dermatological disorders

In the ASSESS cohort (Table 5), patients with active cutaneous involvement in the ESSDAI domain had a higher prevalence of peripheral neuropathy ($p < 0.001$), muscular involvement ($p < 0.01$), biological involvement ($p < 0.05$) and haematologic involvement ($p < 0.05$) compared with that in the control group. These patients more often had a history of arthritis ($p < 0.01$) and splenomegaly ($p < 0.05$) and had a higher level of gamma globulin ($p < 0.01$) compared with the control group. Patients with dermatological activity did not differ from the others in terms of the use of immunosuppressive medications. The mean ESSDAI score was higher in patients with cutaneous involvement than in those without ($p < 0.001$), even after exclusion of the cutaneous domain ($p < 0.05$).

In the TEARS cohort, patients with a VAS cutaneous dryness score ≥ 50 had significantly higher pain scores on the VAS ($p < 0.01$), global dryness scores on the VAS ($p < 0.001$) and ESSPRI scores (71.1 ± 15.2 vs 58.9 ± 15.3 , $p < 0.001$) than those with VAS cutaneous dryness < 50 (Table 6).

4. Discussion

In our study, the prevalence of cutaneous signs included in the cutaneous domain of the ESSDAI score at inclusion was 4.1%, 5.3% and 6.4% in the ASSESS, DiapSS and TEARS cohorts, respectively. However, the cutaneous domain of ESSDAI is limited to few signs and does not include dryness, which is the most common manifestation of the disease. Moreover,

as in many studies, two of our three study populations were not systematically examined by a dermatologist, and although most specific signs of pSS were detected by the rheumatologists, some other unspecific signs were probably not detected.

Cutaneous manifestations contributing to the ESSDAI value are erythema multiforme, cutaneous vasculitis, the most frequent being vascular purpura, and urticarial vasculitis (1).

Vasculitis corresponds to necrotizing or inflammatory lesions of the vascular walls linked to an immunological mechanism. According to the recent dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012)(12), Sjögren syndrome vasculitis is often either recurrent macular vasculitis in hypergammaglobulinemia or cryoglobulinemic vasculitis.

There is wide variability in the prevalence of cutaneous vasculitis in previous studies, ranging from 4.3% to 30.6% (5,13–29). In the ASSESS cohort, the prevalence of cutaneous vasculitis in the ESSDAI score was 16.4%. These results are consistent with previous reports indicating that approximately 15% of patients with pSS have manifestations of cutaneous vasculitis reported in the ESSDAI score (30,31). Recently, Retamozo et al. (32) reported that cutaneous ESSDAI was the 4th most common extraglandular manifestation (10%) in a cohort of 6331 patients with pSS in order of frequency.

Moreover, in the ASSESS cohort, cutaneous involvement in the ESSDAI domain including cutaneous vasculitis is associated with a more severe disease and systemic disease activity; these results are consistent with those of Kittridge et al. in 2011 (33).

Subcutaneous lupus (SCLE), also known as annular erythema, has long been considered an exclusive cutaneous feature of Asian patients with pSS, but Brito-Zerón (13), in a retrospective study, found annular erythema in nearly 35/377 (9%) pSS patients, including Caucasian patients. None of the patients in the ASSESS cohort had any current or past SCLE, but that observation can be explained by the fact that patients have not been systematically examined by dermatologists and consequently there may have been underdiagnosed cases of SCLE.

In the ASSESS cohort, patients with active cutaneous involvement in the ESSDAI domain had a higher prevalence of peripheral neuropathy and muscular involvement; these patients also more often had a history of arthritis; these results are consistent with 2004 Spanish study (15). Furthermore, patients in our cohort with active cutaneous involvement in the ESSDAI domain had a higher level of gamma globulin. Quartuccio et al, in 2017 (30), confirmed that purpuras associated with hypergammaglobulinemia were associated with benign proliferation of B cells, whereas purpura with cryoglobulinemia was associated with systemic vasculitis

with complement activation and increased risk of lymphoma. In the ASSESS cohort, none had lymphoma at the time of inclusion.

Cutaneous dryness, xeroderma or cutaneous xerosis is partly genetically determined. It is a part of the phenotype of each individual, and it changes in the course of life. Nevertheless, it is also clearly associated with Sjögren syndrome, in which it is the most frequently found skin manifestation (23-67%)(34–37). In the TEARS cohort, the VAS scores for cutaneous dryness were collected at baseline. Defining skin xerosis according to the VAS score corresponding to the patient's perception is an interesting approach to evaluating the impact on the patient's quality of life, which can be underestimated if the xerosis is not objectified by the clinician; indeed, in the TEARS cohort, patients with VAS cutaneous dryness ≥ 50 had significantly higher VAS pain scores, VAS global dryness scores and ESSPRI scores. Approximately half of the patients had a cutaneous dryness VAS ≥ 50 , which is consistent with the results of previous studies (27,34,35,38,39).

Moreover, patients with cutaneous EVA dryness ≥ 50 did not have more eye or oral dryness, which is consistent with the pathophysiological mechanism defended by Bernacchi and Engelke (36,40).

In the DiapSS cohort, nearly one-third of the pSS patients had cutaneous involvement, but only 5.3% had cutaneous involvement considered in the ESSDAI. Patients who had a dermatological visit had more skin involvement not taken into account in the ESSDAI. The evaluation of the cutaneous lesions was carried out in general by Sjögren syndrome experts, often rheumatologists and internists, using the ESSDAI score, which can underestimate non-specific cutaneous effects of this syndrome. According to a recent study (32), the percentage of patients with pSS with cutaneous features outside of the ESSDAI was 0.9%. The ESSDAI score is an interesting tool to judge the activity of the disease but does not seem to be suitable for the diagnosis of pSS or for the routine evaluation of all skin disorders. Close collaboration with the dermatologist is justified for detecting nonspecific lesions and for the management of these disorders (34,35).

Our study has several limitations. First, all the study centres were located in France. Second, patients in the 3 cohorts did not meet the same inclusion criteria, which may have led to selection bias. Finally, the evaluation of dermatological involvement was different in our 3 cohorts. Our study also has strengths, including 3 cohorts with a large number of patients, sufficient for the evaluation of the most common cutaneous manifestation and good representativity given the distribution of the included centres throughout France. The different criteria for assessing the dermatological involvement between the 3 cohorts may be a

weakness of the study but also a strength, as it allowed a more general vision of the cutaneous lesions in the pSS population.

To conclude, the dermatological signs included in the ESSDAI activity index are rare. These active skin disorders are associated with ESSDAI activity in various domains (muscle, peripheral neurological, haematological and biological). Systematic examination by a dermatologist would give a better estimation of specific and non-specific cutaneous manifestations of Sjögren syndrome [Appendix A, Figure S1; See the supplementary material associated with this article online]. The most common cutaneous involvement, skin dryness, is not included in the disease endpoints, so it should be evaluated by a specific VAS.

COMPETING INTERESTS: The authors have no competing interests to declare

FUNDINGS: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. *RMD Open*. 2015;1(1):e000022.
2. Roguedas A-M, Youinou P, Lemasson G, Pennec Y-L, Misery L. Primary Gougerot-Sjogren syndrome: a dermatological approach. *J Eur Acad Dermatol Venereol*. 2006 Mar;20(3):243–7.
3. Roguedas AM, Misery L, Sassolas B, Le Masson G, Pennec YL, Youinou P. Cutaneous manifestations of primary Sjögren's syndrome are underestimated. *Clin Exp Rheumatol*. 2004 Oct;22(5):632–6.
4. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum*. 1994 Feb;37(2):187–92.
5. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. *Rheumatol Oxf Engl*. 2014 May;53(5):839–44.
6. Carvajal Alegria G, Guellec D, Devauchelle-Pensec V, Saraux A. Is there specific neurological disorders of primary Sjögren's syndrome? *Joint Bone Spine*. 2015 Mar;82(2):86–9.
7. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis*. 2002 Jun 1;61(6):554–8.
8. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. *Arthritis Care Res*. 2012 Apr;64(4):475–87.
9. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis*. 2017 Jan;76(1):9–16.
10. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. *Ann Rheum Dis*. 2011 Jun;70(6):968–72.
11. Orgeolet L, Foulquier N, Misery L, Redou P, Pers J-O, Devauchelle-Pensec V, et al. Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren's syndrome. *Rheumatol Oxf Engl*. 2019 Aug 31;
12. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013 Jan;65(1):1–11.
13. Brito-Zerón P, Retamozo S, Akasbi M, Gandía M, Perez-De-Lis M, Soto-Cardenas M-J, et al. Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. *Lupus*. 2014 Feb;23(2):166–75.
14. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. *Arthritis Rheum*. 2002 Mar;46(3):741–7.
15. Ramos-Casals M, Anaya J-M, García-Carrasco M, Rosas J, Bové A, Claver G, et al.

- Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. *Medicine (Baltimore)*. 2004 Mar;83(2):96–106.
16. Ramos-Casals M, Brito-Zerón P, Perez-De-Lis M, Jimenez I, Blanco M-J, Bove A, et al. Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria. *Clin Rev Allergy Immunol*. 2010 Apr;38(2–3):178–85.
 17. Martel C, Gondran G, Launay D, Lalloué F, Palat S, Lambert M, et al. Active immunological profile is associated with systemic Sjögren's syndrome. *J Clin Immunol*. 2011 Oct;31(5):840–7.
 18. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. *Rheumatol Oxf Engl*. 2006 Feb;45(2):187–91.
 19. García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. *Medicine (Baltimore)*. 2002 Jul;81(4):270–80.
 20. Friedman JA, Miller EB, Green L, Huszar M, Schattner A. A community-based cohort of 201 consecutive patients with primary Sjögren's syndrome in Israel: Ashkenazi patients compared with those of Sephardic descent. *Clin Exp Rheumatol*. 2006 Jun;24(3):274–80.
 21. Ter Borg EJ, Kelder JC. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome : A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort. *Rheumatol Int*. 2017 Jul;37(7):1153–8.
 22. Ramos-Casals M, Cervera R, Yagüe J, García-Carrasco M, Trejo O, Jiménez S, et al. Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. *Semin Arthritis Rheum*. 1998 Dec;28(3):200–5.
 23. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. *Ann Rheum Dis*. 2001 May;60(5):467–72.
 24. Hernandez-Molina G, Michel-Peregrina M, Bermúdez-Bermejo P, Sánchez-Guerrero J. Early and late extraglandular manifestations in primary Sjögren's syndrome. *Clin Exp Rheumatol*. 2012 Jun;30(3):455.
 25. Haga H-J, Andersen DT, Peen E. Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren's syndrome, and its association to clinical manifestations. *Clin Rheumatol*. 2011 Mar;30(3):369–72.
 26. Katayama I. Abberant Sudomotor Functions in Sjögren's Syndrome: Comparable Study with Atopic Dermatitis on Dry Skin Manifestation. *Curr Probl Dermatol*. 2016;51:62–74.
 27. Bernacchi E, Amato L, Parodi A, Cottoni F, Rubegni P, De Pità O, et al. Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. *Clin Exp Rheumatol*. 2004 Feb;22(1):55–62.
 28. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. *Rheumatol Oxf Engl*. 2015 Dec;54(12):2230–8.
 29. Brito-Zerón P, Acar-Denizli N, Ng W-F, Horváth IF, Rasmussen A, Seror R, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. *Rheumatology*. 2019 Dec 24;kez578.
 30. Quartuccio L, Baldini C, Priori R, Bartoloni E, Carubbi F, Alunno A, et al. Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. *J Rheumatol*. 2017;44(8):1179–83.

31. Ramos-Casals M, Brito-Zerón P, Solans R, Camps M-T, Casanovas A, Sopena B, et al. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). *Rheumatol Oxf Engl*. 2014 Feb;53(2):321–31.
32. Retamozo S, Acar-Denizli N, Rasmussen A, Horváth IF, Baldini C, Priori R, et al. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. *Clin Exp Rheumatol*. 2019 Jun;37 Suppl 118(3):97–106.
33. Kittridge A, Routhouska SB, Korman NJ. Dermatologic Manifestations of Sjögren Syndrome. *J Cutan Med Surg*. 2011 Jan;15(1):8–14.
34. Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and Mucosal Manifestations of Sjögren's Syndrome. *Clin Rev Allergy Immunol*. 2017 Dec;53(3):357–70.
35. Jhorar P, Torre K, Lu J. Cutaneous features and diagnosis of primary Sjögren syndrome: An update and review. *J Am Acad Dermatol*. 2018 Oct;79(4):736–45.
36. Bernacchi E, Bianchi B, Amato L, Giorgini S, Fabbri P, Tavoni A, et al. Xerosis in primary Sjögren syndrome: immunohistochemical and functional investigations. *J Dermatol Sci*. 2005 Jul;39(1):53–5.
37. Valdes-Rodriguez R, Rowe B, Lee H, Moldovan T, Chan Y, Blum M, et al. Chronic Pruritus in Primary Sjögren's Syndrome: Characteristics and Effect on Quality of Life. *Acta Derm Venereol*. 2017;97(3):385–6.
38. Roguedas A-M, Pers J-O, Lemasson G, Devauchelle V, Tobón GJ, Saraux A, et al. Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjögren's syndrome. *J Autoimmun*. 2010 Nov;35(3):241–7.
39. Markusse HM, Oudkerk M, Vroom TM, Breedveld FC. Primary Sjögren's syndrome: clinical spectrum and mode of presentation based on an analysis of 50 patients selected from a department of rheumatology. *Neth J Med*. 1992 Apr;40(3–4):125–34.
40. Engelke M, Jensen JM, Ekanayake-Mudiyanselage S, Proksch E. Effects of xerosis and ageing on epidermal proliferation and differentiation. *Br J Dermatol*. 1997 Aug;137(2):219–25.

Table 1: Characteristics of patients with pSS included in the three cohorts: ASSESS, TEARS and diapSS

| | ASSESS N=395 pSS | TEARS N=110 pSS | diapSS N=180 sicca | diapSS N=139 pSS |
|---------------------------------------|-----------------------------|----------------------------|-------------------------------|-----------------------------|
| Mean (SD) | | | | |
| Age, years | 57.9 (+/-12.1) | 54.3 (13.7) | 55.4 (+/-13.9) | 56.3 (+/-13.2) |
| time since first symptom | 6.5 (+/-5.8) | 8.0 (+/-6.7) | 5.9 (+/-6.5) | 7.1 (+/-7.9) |
| ESSDAI score | 4.8 (+/-5.5) | 10.1 (+/-6.8) | 3.9 (+/-5.7) | 5.1 (+/-5.7) |
| ESSPRI score | 53.5 (+/-21.2) | 64.2 (+/-16.2) | 56.3 (+/-25.8) | 59.4 (+/-25.8) |
| n/N (%) | | | | |
| Female sex F/M (% F) | 367/25 (92.9) | 109/1 (99.1) | 213/18 (92.2) | 87/7 (92.6) |
| Anti-SSA antibodies | 228/385 (59.2) | 90/110 (81.8) | 64/230 (27.8) | 29/94 (30.8) |
| Anti-SSB antibodies | 129/385 (33.5) | - | 29/229 (12.7) | 13/94 (13.8) |
| Cutaneous involvement on ESSDAI score | 16/389 (4.1) | 7/110 (6.4) | 9/228 (3.9) | 8/91 (8.8) |

ESSDAI= European League Against Rheumatism Sjögren syndrome disease activity index
disease activity index

ESSPRI = European League Against Rheumatism Sjögren Syndrome Patient Reported Index

Anti-SSA = anti-Sjögren syndrome A antibodies

Anti-SSB = anti-Sjögren syndrome B antibodies

Table 2: Prevalence of cutaneous manifestations in the ASSESS cohort

| | Present at inclusion | Previous involvement | Any moment |
|----------------|-----------------------------|-----------------------------|-------------------|
| | N=391 | N=391 | N=391 |
| n/N (%) | | | |
| Purpura, n (%) | 9 (2.3) | 35 (8.9) | 44 (11.3) |
| Livedo, n (%) | 4 (10.2) | 12 (3.1) | 16 (4.1) |
| Ulcer, n (%) | 1 (0.2) | 3 (0.8) | 4 (1.0) |

Table 3: Cutaneous involvement observed by a rheumatologist in the diapSS cohort

| | pSS | Sicca or other manifestations suggestive of pSS without pSS |
|--|----------------|--|
| | N = 139 | N = 180 |
| n/N (%) | | |
| Cutaneous involvement on ESSDAI score | 7 (5.0) | 10 (5.5) |
| - Low activity | 0 | 3 |
| - Moderate activity | 6 | 6 |
| - High activity | 1 | 1 |
| Cutaneous involvement not taken into account in the ESSDAI score | 39 (28.1) | 35 (19.4) |

Table 4: Cutaneous involvement detected in patients with pSS in the diapSS cohort

| | Dermatological examination N =76 | No dermatological examination N = 63 |
|---|---|---|
| n/N (%) | | |
| Cutaneous involvement on ESSDAI score | 5/76 (6.6) | 2/63 (1.6) |
| Cutaneous involvement not taken into account in the ESSDAI score ** | 29/76 (38.2) | 10/63 (15.9) |

**P < 0.01

Table 5: Characteristics of patients and factors associated with dermatological involvement in the ASSESS cohort

| | Cutaneous manifestations | No cutaneous manifestations |
|-------------------------------------|---------------------------------|------------------------------------|
| n/N (%) | | |
| Lymphadenopathy | 1/16 (6.3) | 11/374 (2.9) |
| Glandular | 3/16 (18.8) | 44/374 (11.8) |
| Articular | 6/16 (37.5) | 67/374 (17.9) |
| Pulmonary | 0/16 (0) | 57/372 (15.3) |
| Renal | 1/16 (6.3) | 10/374 (2.7) |
| Muscular** | 3/16 (18.8) | 10/373 (2.7) |
| Peripheral nervous system (PNS)*** | 4/16 (25) | 34/373 (9.1) |
| Central nervous system (CNS) | 0/16 (0) | 8/374 (2.1) |
| Biological* | 8/16 (50) | 138/371 (37.2) |
| Haematologic* | 7/16 (43.8) | 55/373 (14.7) |
| History of arthritis** | 12/16 (75) | 154/374 (41.2) |
| History of splenomegaly* | 2/16 (12.5) | 10/37 (2.7) |
| Cryoglobulinemia | 4/16 (25) | 53/321 (16.5) |
| Anti-DNA | 1/16 (6.3) | 37/320 (11.6) |
| Anti-SSA | 13/16 (81.3) | 215/369 (58.3) |
| Anti-SSB | 9/16 (56.3) | 120/369 (32.5) |
| History of lymphoma | 0/16 (0) | 18/379 (4.7) |
| Corticosteroids ¹ | 8/16 (50) | 207/376 (55.1) |
| Corticosteroids of the last visit | 2/16 (12.5) | 38/252 (15.1) |
| Plaquenil ¹ | 11/16 (68.8) | 209/376 (55.6) |
| Plaquenil of the last visit | 4/12 (33.3) | 60/257 (23.3) |
| Methotrexate ¹ | 1/16 (6.3) | 50/375 (13.3) |
| Rituximab ¹ | 2/16 (12.5) | 19/375 (5.1) |
| Mean +/-SD | | |
| Gamma globulin levels** | 23.1 +/-7.3 | 18.5 +/-8.1 |
| ESSDAI score*** | 14.5 (6.8) | 4.4 (5.1) |
| ESSDAI score excluding skin points* | 8.1 (6.2) | 4.4 (5.1) |

*** P < 0.001

**P < 0.01

* P < 0.05

¹ Current use and prior to inclusion.

Anti-DNA = deoxyribonucleic acid antibodies, Anti-SSA = anti-Sjögren syndrome A antibodies, Anti-SSB = anti-Sjögren syndrome B antibodies

Table 6: Factors associated with dermatological involvement in the TEARS cohort

| | VAS cutaneous dryness score \geq 50 N = 53 | VAS cutaneous dryness score < 50 N = 57 |
|----------------------------------|--|---|
| n/N (%) | | |
| Cutaneous involvement on ESSDAI | 3 (5.7) | 4 (7.0) |
| Raynaud's Syndrome | 17 (32.1) | 21 (36.8) |
| Oral symptoms | 53 (100) | 55 (96.5) |
| Dry mouth | 50 (94.3) | 52 (94.5) |
| Ocular symptoms | 51 (96.4) | 52 (91.2) |
| Dry eyes | 46 (90.2) | 46 (88.5) |
| Lymphadenopathy | 5 (9.4) | 2 (3.5) |
| Glandular | 31 (59.6) | 39 (68.4) |
| Articular | 17 (32.1) | 14 (24.6) |
| Pulmonary | 5 (9.4) | 10 (17.5) |
| Renal | 1 (0.2) | 3 (0.5) |
| Muscular | 2 (0.4) | 1 (0.2) |
| Neurologic | 6 (11.3) | 10 (17.5) |
| Mean +/-SD | | |
| Pain VAS score, <i>mm</i> ** | 61.7 +/- 28.2 | 46.8 +/-27.0 |
| Dryness VAS score, <i>mm</i> *** | 79.4 +/- 15.2 | 62.5 +/-21.7 |
| Fatigue VAS score, <i>mm</i> | 72.2 +/- 18.2 | 67.5 +/- 18.9 |
| ESSPRI score *** | 71.1 +/- 15.2 | 58.9 +/- 15.4 |

*** P < 0.001

**P < 0.01

VAS = visual analogue scale, ESSPRI = EULAR Sjögren Syndrome Patient Reported Index